Oncocyte Reports Q1 2025 Results and Business Progress
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 12 2025
0mins
Should l Buy ?
Source: Newsfilter
Financial Performance: Oncocyte Corp. reported $2.1 million in pharma services revenue for Q1 2025, achieving a gross margin of 62%, up from 40% in the previous quarter, while also planning to advance their clinical molecular diagnostic test kit for transplant rejection testing and rename the company to reflect its broader market focus.
Clinical Trial and Product Development: The company has completed the design for its clinical trial and expects participation from three top U.S. transplant centers, aiming for FDA clearance of its transplant test kit by 2026, while also expanding its GraftAssure product line and enhancing operational efficiencies in its Nashville lab.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
